This meeting took place in 2015


Here are the related meetings in 2019:
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Tumor Immunology: Multidisciplinary Science Driving Combination Therapy (J7)


Organizer(s) Elizabeth M. Jaffee and Axel Hoos
February 8—13, 2015
Fairmont Banff Springs • Banff, Alberta Canada
Discounted Abstract Deadline: Oct 9, 2014
Abstract Deadline: Nov 12, 2014
Scholarship Deadline: Oct 9, 2014
Discounted Registration Deadline: Dec 9, 2014

Sponsored by Astellas Pharma Inc., Genmab A/S, Gilead Sciences, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., NeoStem, Inc., Regeneron Pharmaceuticals, Inc. and TESARO, Inc. Supported by an educational donation provided by Amgen.


Summary of Meeting:
The field of cancer immunotherapy is evolving rapidly as a result of key scientific and developmental principles that have been discovered in recent years. New technologies together with this new knowledge have given birth to the next generation of vaccines, adoptive cellular therapies and T cell modulating agents, all of which are being investigated in preclinical models and in patients. This new era has also revealed the complex network of signaling pathways within the tumor microenvironment that currently favors the pro-carcinogenic process, but new evidence also demonstrates that this process can be altered with agents that modulate these pathways resulting in antitumor immunity. Much is being learned about the interdependency of these pathways with each other and with the non-immune cellular components within the tumor microenvironment that include the tumor, epithelial and endothelial cells, and the stroma. Thus, optimizing outcomes for patients will likely come from successfully combining immunotherapies with each other and with other classes of therapies. This will require the integration of different scientific approaches ranging from small molecule targeted therapies to complex biologics, as well as addressing molecular pathways in all of the cell subtypes within the tumor microenvironment. This conference brings together experts from academia and industry who have pioneered these areas of immunologic science, and will showcase the integration of this increasingly complicated knowledge into rapid translation into clinical applications.

View Meeting Program

Scholarships/Awards

Keystone Symposia Future of Science Fund Scholarship Recipients

Amy-Jo Casbon
Amgen, USA

National Institute of General Medical Sciences (NIGMS) Ancillary Training Program Scholarship Recipients

Elliott Joseph Brea
Weill Cornell Medical College, USA

Sachi Nakashima Memorial Fellowship Scholarship Scholarship Recipients

Marit Martha van Buuren
Neon Therapeutics, USA

The Elkes Foundation Scholarship Recipients

Lelisa F. Gemta
University of Virginia, USA

Nikhil S. Joshi
Yale University School of Medicine, USA